Abstract: Imidazopyridine compounds that contain sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
December 17, 2002
Date of Patent:
February 24, 2004
Assignee:
3M Innovative Properties Company
Inventors:
Joseph F. Dellaria, Chad A. Haraldson, Philip D. Heppner, Kyle J. Lindstrom, Byron A. Merrill
Abstract: The imidazonaphthyridine compound, 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine, induces the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compound exhibits antiviral and antitumor properties. Methods of preparing the compound and intermediates useful in the preparation of the compound are also disclosed.
Abstract: Methods of preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines are disclosed. These compounds function as antiviral agents, they induce the biosynthesis of various cytokines including interferon, and they inhibit tumor formation in animal models.
Type:
Grant
Filed:
May 13, 2003
Date of Patent:
February 3, 2004
Assignee:
3M Innovative Properties Company
Inventors:
John F. Gerster, Stephen L. Crooks, Kyle J. Lindstrom
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
January 27, 2004
Assignee:
3M Innovative Properties Company
Inventors:
Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and sulfonamide or sulfamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
June 7, 2002
Date of Patent:
January 13, 2004
Assignee:
3M Innovative Properties Company
Inventors:
Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill, Ralph R. Roberts, Ai-Ping Wei
Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
Type:
Grant
Filed:
September 12, 2002
Date of Patent:
January 13, 2004
Assignee:
3M Innovative Properties Company
Inventors:
John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain sulfonamide or sulfonamide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
June 7, 2002
Date of Patent:
January 13, 2004
Assignee:
3M Innovative Properties Company
Inventors:
Phillip D. Heppner, Leslie J. Charles, Joseph F. Dellaria, Bryon A. Merrill, John W. Mickelson
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
December 30, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Leslie J. Charles, Joseph F. Dellaria, Philip D. Heppner, Bryon A. Merrill, John W. Mickelson
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
June 7, 2002
Date of Patent:
December 23, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Jason D. Bonk, Joseph F. Dellaria, Bryon A. Merrill, Matthew R. Radmer
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
December 16, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Joseph F. Dellaria, Bryon A. Merrill, Matthew R. Radmer
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and heterocyclyl or heteroaryl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
December 16, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Leslie J. Charles, Joseph F. Dellaria, George W. Griesgraber, Philip D. Heppner, Karl J. Manske, John W. Mickelson, Michael J. Rice
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
June 7, 2002
Date of Patent:
December 16, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Byron A. Merrill
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
June 7, 2002
Date of Patent:
December 9, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and amide functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
December 9, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
Abstract: Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and urea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.
Type:
Grant
Filed:
December 6, 2001
Date of Patent:
December 2, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Stephen L. Crooks, George W. Griesgraber, Philip D. Heppner, Bryon A. Merrill
Abstract: Imidazonaphthyridine compounds that have a urea containing substituent at the 1-position induce the biosynthesis of cytokines such as interferon and tumor necrosis factor. The compounds exhibit antiviral and antitumor properties. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.
Abstract: Dye labeled imidazonaphthyridine, imidazopyridine and imidazoquinoline compounds having immune response modulating activity are disclosed. The compounds are useful, inter alia, for determining the binding and/or receptor sites of the molecules.
Type:
Grant
Filed:
February 19, 2002
Date of Patent:
October 7, 2003
Assignee:
3M Innovative Properties Company
Inventors:
Michael J. Rice, Mark A. Tomai, Ai-Ping Wei
Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
Type:
Grant
Filed:
September 12, 2002
Date of Patent:
September 30, 2003
Assignee:
3M Innovative Properties Company
Inventors:
John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
Type:
Grant
Filed:
July 10, 2002
Date of Patent:
September 30, 2003
Assignee:
3M Innovative Properties Company
Inventors:
John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek